anticompetitive conduct, Antitrust, Antitrust violations, B. Braun, Baxter, Braun, Brazil, cancer, Cartel, catheters, Competition, deaths, deregulation, Drug shortage, Ebola, Eric T. Schneiderman, flu, flu outbreak, free enterprise, FTC, Grand Jury, greed, Hospira, ICU Medical, injectable medicines, IV saline industry, IV saline solution probe, IV saline solutions, medical care costs, Monopoly Capital, NY AG office, patients, Pfizer, Price Fixing, profits, pumps, Quality standards, regulations, saline bags, saline solution shortage, tubing, US Senate
Pfizer, Baxter, and ICU Medical, most likely Germany’s B. Braun, and perhaps others, have been subpoenaed in a criminal investigation. Meanwhile how many have and will die because of a shortage of saline bags during the current US flu outbreak? The price increase was 200-300% and more between 2013 and 2015. By now it may be 600% or 1000% – who knows? Where are the journalists?
From a Baxter sec report: “On April 12, 2017, one of the Company’s employees received a grand jury subpoena issued by the United States District Court for the Eastern District of Pennsylvania, prepared by the U.S. Department of Justice, Antitrust Division, pursuant to a criminal investigation.
The subpoena calls for production of documents and testimony regarding the manufacturing, selling, pricing and shortages of intravenous solutions and containers (including saline solutions and certain other injectable medicines sold by the Company) and communications with competitors regarding the same.
The Company is cooperating with the U.S. Department of Justice on this investigation. As previously disclosed, the New York Attorney General’s office has previously requested that the Company provide information regarding business practices in the IV saline industry.” https://www.sec.gov/Archives/edgar/data/10456/000119312517124024/d365699d8k.htm
The CEO of Baxter got his degree in Brazil and most likely is from there: https://en.wikipedia.org/wiki/José_E._Almeida
“Oct 26 2015
Blumenthal, Lee, Klobuchar, Hatch Urge FTC to Investigate Antitrust Violations Connected to IV Solution Shortages, Increasing Costs of Hospital Operations and Patient Care
“One health care expert has claimed that this could make the saline solution shortage the most expensive drug shortage in U.S. history.”
“Rising healthcare costs are one of the most pressing concerns facing this nation, and ensuring that anticompetitive conduct does not further increase those costs is one of the FTC’s most important charges.”
(WASHINGTON, D.C.) – Today, a bipartisan group of U.S. Senators Richard Blumenthal (D-Conn.), Mike Lee (R-Utah), Amy Klobuchar (D-Minn.) and Orrin G. Hatch (R-Utah) urged the Federal Trade Commission (FTC) to investigate possible illegal collusion by saline solution manufacturers. Senators Lee and Klobuchar are the Chairman and Ranking Member, respectively, of the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, and Senator Hatch is the former Chairman of the full Judiciary Committee.
In a letter to FTC Chairwoman Edith Ramirez, the senators noted the nation’s shortage of saline solution since 2013 and the failure of the three companies that provide all of the saline solution in the U.S. to end the shortage. As saline solution is a necessity in hospitals across the country, actions by manufacturers indicate possible collusive behavior to exploit the shortage to increase company profits and harm competitors, resulting in higher costs for the nation’s hospitals, patients, and overall healthcare system.
“Since the saline shortage began in late 2013, suppliers are reported to have increased their prices by 200-300 percent,” the senators wrote. “This equates to increased annual costs to individual hospitals in the range of hundreds of thousands to millions of dollars.”
“Price increases often help clear shortages, but in this case the shortage is still ongoing after nearly two years, raising questions about the incentives of the saline suppliers to solve this problem and about possible coordination among them.”
Instead of addressing the shortage, the cost of saline has continued to rise and manufacturers have increasingly capitalized on the shortage, specifically by “imposing even greater price increases on customers who do not also purchase additional non-saline products, effectively tying saline sales to other products such as the pumps, tubing, and catheters through which saline is delivered to the patient.” The senators noted, “If true, these actions pose a potential risk to the wellbeing of patients by forcing hospitals to purchase products they may believe to be clinically inferior and add significant costs to our health care system.”
“…the saline suppliers’ ability to extract several-hundred-percent price increases and to lock their customers into long term contracts is likely reducing their incentive to alleviate this troubling shortage, which, in turn, further exacerbates the shortage and results in consumer harm.”
Full text of the letter is below.
Dear Chairwoman Ramirez:
We are writing today to express our concern about the ongoing shortage of saline solution in the United States, and to urge the Federal Trade Commission (FTC) to investigate whether saline suppliers may be taking advantage of this shortage in ways that run afoul of antitrust law and pose risks to patient care.
The nation has been facing a shortage of saline solution since at least 2013, when the Food and Drug Administration added it to the drug shortage list. Saline solution, which is delivered to patients through intravenous (IV) pumps, is a critical input to the United States healthcare system. It is crucial to the treatment regimen of everything from Ebola to cancer to the flu. Hospitals rely on saline every day to dilute medication, hydrate patients, and complete countless procedures. More than a billion units of saline are used in the U.S. every year, and no hospital in America can properly function without it.
Three companies provide all of the saline solution used in the United States – Baxter, Hospira and B. Braun. While all three companies have publicly spoken to their commitment to ending the saline shortage, it has persisted for two years even as prices have risen. Since the saline shortage began in late 2013, suppliers are reported to have increased their prices by 200-300 percent. This equates to increased annual costs to individual hospitals in the range of hundreds of thousands to millions of dollars. One health care expert has claimed that this could make the saline solution shortage the most expensive drug shortage in U.S. history.
Even more troubling, hospitals have reported that all three saline suppliers are imposing even greater price increases on customers who do not also purchase additional non-saline products, effectively tying saline sales to other products such as the pumps, tubing, and catheters through which saline is delivered to the patient. If true, these actions pose a potential risk to the wellbeing of patients by forcing hospitals to purchase products they may believe to be clinically inferior and add significant costs to our health care system.
Other hospitals have reported that their saline supplier indicated that the hospital would not be able to purchase any saline at any price unless the hospital also purchased additional products. While prices tend to increase during a shortage, these price increases appear to be outside the bound of natural market forces. Price increases often help clear shortages, but in this case the shortage is still ongoing after nearly two years, raising questions about the incentives of the saline suppliers to solve this problem and about possible coordination among them.
The ongoing shortage, the fact that the shortage has not cleared even with significant price increases, and the behavior reported by hospitals raises questions about potential coordination between the saline suppliers. Even absent coordination, the saline suppliers’ ability to extract several-hundred-percent price increases and to lock their customers into long term contracts is likely reducing their incentive to alleviate this troubling shortage, which, in turn, further exacerbates the shortage and results in consumer harm.
Rising healthcare costs are one of the most pressing concerns facing this nation, and ensuring that anticompetitive conduct does not further increase those costs is one of the FTC’s most important charges. We find the conduct described above troubling and deserving of close and thorough scrutiny by the FTC. We urge the FTC to formally investigate whether the saline suppliers’ apparent anticompetitive conduct is harming consumers and running afoul of the antitrust laws.”
“Pfizer subpoenaed in U.S. intravenous saline solution probe
Reuters April 19, 2017 Nate Raymond
BOSTON – Pfizer Inc has received grand jury subpoenas from the U.S. Justice Department in connection with an antitrust investigation focusing on drugmakers that market intravenous saline solutions. The drugmaker disclosed the subpoenas in a statement on Wednesday after ICU Medical Inc, which recently acquired Pfizer’s global infusion therapy business, and Baxter International Inc said they received similar subpoenas. ICU Medical said the probe related to Hospira Infusion Systems, which it purchased in February from Pfizer, after Pfizer had acquired it in a merger with Hospira Inc in 2015… The probe comes amid a shortage of intravenous saline solutions commonly used to hydrate hospital patients that dates back to late 2013, when drug companies began notifying hospitals that they might experience delivery delays…” Read the entire article here: Permalink: https://www.klobuchar.senate.gov/public/index.cfm/2017/4/pfizer-subpoenaed-in-u-s-intravenous-saline-solution-probe
Excerpt from a 2014 NPR article on a shortage of saline solution: “Shortage Of Saline Solution Has Hospitals On Edge” – “She says it’s challenging to make sure saline products are sterile. If you swallow a pill with a little bit of dirt on it, you’ll probably be fine. But contaminated saline injected into your vein could cause a big problem.
That’s why the FDA sets strict quality standards for the facilities that manufacture saline and other IV drugs, but the agency has to find a delicate balance between safety and supply.
Some suppliers suggest that keeping up with the FDA’s standards is too onerous and may be playing a part in the shortage….” Read more here: https://www.npr.org/sections/health-shots/2014/06/22/323679204/shortage-of-saline-solution-has-hospitals-on-edge
Prediction: Trump Admin will use current shortage as excuse to reduce US FDA standards resulting in more contamination and serious illness and death.